<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01935622</url>
  </required_header>
  <id_info>
    <org_study_id>VCU HM14393</org_study_id>
    <nct_id>NCT01935622</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy</brief_title>
  <acronym>DOXY-HF</acronym>
  <official_title>Phase II Study of Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Virginia Commonwealth University IRB</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of
      systemic inflammation.

      Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful
      anti-inflammatory effects.

      In this study we plan to determine the effects of Doxycycline in patients with stable heart
      failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and
      ventilator efficiency measured with a cardiopulmonary test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study of Safety and Efficacy of Doxycycline in Patients with Non-Ischemic
      Cardiomyopathy Population, we will enroll 24 patients with a clinical diagnosis of heart
      failure and non-ischemic cardiomyopathy (recent imaging study documenting LV ejection
      fraction &lt;50%, and no history of coronary or ischemic heart disease) in a single-center,
      randomized, double-blinded, placebo-controlled clinical trial with allocation 1:1:1 to
      Doxycycline 100 mg twice daily or Doxycycline 20 mg twice daily or Placebo for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Peak aerobic exercise capacity</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Interval change in peak VO2 measured at cardiopulmonary test</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <condition>Systolic Heart Failure (NYHA II-III)</condition>
  <arm_group>
    <arm_group_label>Doxycycline 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 100 mg twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 20 mg twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <arm_group_label>Doxycycline 100 mg</arm_group_label>
    <arm_group_label>Doxycycline 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-ischemic cardiomyopathy (LVEF&lt;40%)

          -  Heart failure NYHA II-III

        Exclusion Criteria:

          -  Age &lt;18

          -  Recent changes (previous 3 months) in HF maintenance medications (beta-blockers,
             angiotensin converting enzyme   [ACE] inhibitors, aldosterone antagonists,
             vasodilators, cardiac glycosides, diuretics)

          -  Hospitalization for worsening HF or acute decompensated HF within the previous 12
             months

          -  History of coronary or ischemic heart disease

          -  Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable
             cardioverter defibrillator (AICD) or coronary revascularization or cardiac surgery

          -  Angina or electrocardiograph (ECG) changes that limit maximum exertion during
             cardiopulmonary exercise testing

          -  Active infection including chronic infection

          -  Active cancer (or prior diagnosis of cancer within the past 10 years)

          -  Recent (&lt;14 days) use of anti-inflammatory drugs (not including NSAIDs), Chronic
             inflammatory disorder (including but not limited to rheumatoid arthritis, systemic
             lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to
             complete the study

          -  Pregnancy

          -  Inability to give informed consent

          -  Other conditions limiting completion of cardiopulmonary exercise test or completion
             of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Abbate</last_name>
    <email>aabbate@vcu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Abbate</last_name>
      <email>aabbate@vcu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>September 4, 2013</lastchanged_date>
  <firstreceived_date>August 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>non-ischemic cardiomyopathy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Doxycycline hyclate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
